Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study.

Dystrophic epidermolysis bullosa (EB) is a family of rare genetic dermatological conditions. Recent evidence indicated that in addition to its detrimental implications on patient health-related quality of life (HRQoL), there are substantial socioeconomic cost implications, especially regarding direct non-medical costs. This study aims to understand the burden of dystrophic EB (DEB) in Europe, using a primary EB patient-level dataset. A bottom-up, cross-sectional, study design was adopted for non-institutionalised patients diagnosed with EB who received outpatient care across EU5 countries: France, Germany, Italy, Spain, and the United Kingdom. A prevalence-based approach was used to estimate resource utilisation from a societal perspective, including direct (medical and non-medical) and indirect costs for patients and caregivers. Patient and caregiver outcomes were obtained using the EQ-5D questionnaire. A sample of 91 DEB patients was analysed. Overall, average EU5 annual cost per patient was estimated at €53,359, ranging from €18,783 (France) to €79,405 (Germany). Average EU5 annual direct medical costs were estimated at €8357 (15.7% of total), ranging from €5658 (France) to €12,576 (Germany); average direct non-medical costs were estimated at €41,353 (77.5% of total), ranging from €11,961 (France) to €57,000 (Germany); and average indirect costs were estimated at €3649 (6.8% of total), ranging from €1025 (Italy) to €9930 (United Kingdom). Costs varied across patients with different disability but also between children and adults. The mean EQ-5D index score for adult DEB patients ranged between 0.304 (United Kingdom) and 0.541 (Germany), with an EU5 average of 0.456, whereas the mean EQ-5D visual analogue scale score ranged between 47.5 (Germany) and 70.0 (France), with an EU5 average of 61.9. Limitations included potential patient selection bias, recall bias, and exclusion of bandaging and related costs. The study revealed a substantial socioeconomic burden for DEB in Europe, attributable mostly to high direct non-medical costs, with the majority of patients requiring support from caregivers at home. Compared to the average economic burden of the overall EB patient population, costs for DEB patients are higher across all components of direct medical, direct non-medical and indirect costs.

Angelis A ，Mellerio JE ，Kanavos P 《Orphanet Journal of Rare Diseases》

Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe.

Angelis A ，Kanavos P ，López-Bastida J ，Linertová R ，Oliva-Moreno J ，Serrano-Aguilar P ，Posada-de-la-Paz M ，Taruscio D ，Schieppati A ，Iskrov G ，Brodszky V ，von der Schulenburg JM ，Chevreul K ，Persson U ，Fattore G ，BURQOL-RD Research Network ... -  《-》

Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe.

Kuhlmann A ，Schmidt T ，Treskova M ，López-Bastida J ，Linertová R ，Oliva-Moreno J ，Serrano-Aguilar P ，Posada-de-la-Paz M ，Kanavos P ，Taruscio D ，Schieppati A ，Iskrov G ，Péntek M ，Delgado C ，von der Schulenburg JM ，Persson U ，Chevreul K ，Fattore G ，BURQOL-RD Research Network ... -  《-》

Social/economic costs and quality of life in patients with haemophilia in Europe.

Cavazza M ，Kodra Y ，Armeni P ，De Santis M ，López-Bastida J ，Linertová R ，Oliva-Moreno J ，Serrano-Aguilar P ，Posada-de-la-Paz M ，Taruscio D ，Schieppati A ，Iskrov G ，Gulácsi L ，von der Schulenburg JM ，Kanavos P ，Chevreul K ，Persson U ，Fattore G ，BURQOL-RD Research Network ... -  《-》

Social/economic costs and health-related quality of life in patients with histiocytosis in Europe.

Iskrov G ，Astigarraga I ，Stefanov R ，López-Bastida J ，Linertová R ，Oliva-Moreno J ，Serrano-Aguilar P ，Posada-de-la-Paz M ，Schieppati A ，Taruscio D ，Péntek M ，von der Schulenburg JM ，Kanavos P ，Chevreul K ，Persson U ，Fattore G ，BURQOL-RD Research Network ... -  《-》